Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab.
A 67-year-old woman developed refractory pseudophakic cystoid macular edema (CME) after uneventful phacoemulsification. Three months after an intravitreal injection of bevacizumab (1.25 mg), the CME was completely resolved, with resultant improvement in visual acuity.
Barone
Antonio
A
Department of Ophthalmology, Policlinico di Foggia, University di Foggia, Foggia, Italy. antbarone@infinito.it
Prascina
Francesco
F
Russo
Vincenzo
V
Iaculli
Cristiana
C
Primavera
Vito
V
Querques
Giuseppe
G
Stella
Andrea
A
Delle Noci
Nicola
N
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007267:Injections; D019654:Lens Implantation, Intraocular; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D018918:Phacoemulsification; D011183:Postoperative Complications; D019591:Pseudophakia / Q000188:drug therapy* / Q000209:etiology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab